Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price
Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.
You may also be interested in...
Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.
UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.
Belgium-headquartered UCB has a group of antibody-based products in mid to late-stage clinical studies which will be competing in the dermatology/immune disorders marketplace in the next few years.